Drug Trial Radar · NCT07925190
A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
318
Planned (sponsor's estimate)
Start
Nov 3, 2026
Primary completion
Dec 2029
Study completion Jun 2030
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase III study comparing Mesutoclax + azacitidine versus venetoclax + azacitidine in newly diagnosed acute myeloid leukemia (AML) patients
Conditions
- Acute Myeloblastic Leukemia
Interventions
Mesutoclax (ICP-248)Drug
125 mg QD, orally, until disease progression or other reasons for treatment discontinuation, whichever comes first.
Azacitidine (AZA)Drug
75 mg/m2, Day 1-7 or Day 1-5 and Day 8-9 of each Cycle, by injection
VenetoclaxDrug
400 mg QD, orally, until disease progression or other reasons for treatment discontinuation, whichever comes first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: through the study completion, approximately up to 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.